...
首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German H
【24h】

A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German H

机译:解决霍奇金淋巴瘤晚期晚期强化化疗后需要合并放疗的问题-德国H放射治疗参考中心发起的质量控制计划分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: The role of radiotherapy (RT) after intensive chemotherapy in patients with advanced stage Hodgkin's lymphoma (HL) is still unclear. The German Hodgkin Study Group (GHSG) randomized HD12 trial was designed to test whether consolidative RT in the region of initial bulky disease and of residual disease is necessary after effective chemotherapy. A quality control program based on a multidisciplinary panel of radiation oncologists, radiologists, and medical oncologists who reviewed all patients' staging and restaging imaging was initiated. METHODS AND MATERIALS: A total of 1661 patients aged 16 to 65 years with HL in Stage IIB (large mediastinal mass and/or E-lesions) or Stage III to IV were randomized from January 1999 to January 2003 according to a factorial design between: 8 esc.BEACOPP + RT (arm A), 8 esc.BEACOPP non-RT (arm B), 4+4BEACOPP + RT (arm C), 4+4BEACOPP non-RT (arm D). RESULTS: In the fifth interim analysis, 1449 patients were eligible for the arm comparison with regard to RT. Aftera median observation time of 48 months the FFTF rate was 86% and the OS 92%. The FFTF was 95% in the RT arms A+C and 88% in the non-RT arms B+D: no sequential significant difference. One thousand and eighty four patients were evaluated by the panel. The panel defined initial bulky disease in 800 patients and residual disease in 600 patients. The panel recommended continuation of therapy according to the randomization for 934 of 1084 patients and additive RT independently from the randomization arm for 145 of 1084 patients. CONCLUSIONS: The study showed that RT can be reduced substantially after effective chemotherapy. However, because of the irradiation of 10% of patients in the non-RT arms, equivalent effectiveness of a non-RT strategy cannot be proved. A substantial limitation of consolidative RT according to expert panel recommendations appears to be possible without reducing effectiveness.
机译:目的:在晚期霍奇金淋巴瘤(HL)患者中,强化化疗后放疗(RT)的作用尚不清楚。德国霍奇金研究小组(GHSG)随机进行的HD12试验旨在测试有效化疗后是否需要在最初的大块疾病和残留疾病区域进行巩固性RT。启动了一个由放射肿瘤学家,放射学家和医学肿瘤学家的多学科小组组成的质量控制计划,该小组审查了所有患者的分期和再分期成像。方法和材料:1999年1月至2003年1月,根据析因设计,将1661例年龄在16至65岁的HL在IIB期(大纵隔肿块和/或E病变)或III期至IV期的患者随机分为以下患者: 8 esc.BEACOPP + RT(A组),8 esc.BEACOPP non-RT(B组),4 + 4BEACOPP + RT(C组),4 + 4BEACOPP非RT(A组)。结果:在第五次中期分析中,有1449例患者有资格进行RT的手臂比较。经过48个月的中位观察时间后,FFTF率为86%,OS为92%。 RT组A + C的FFTF为95%,非RT组B + D的FFTF为88%:无连续显着性差异。专家组评估了184位患者。该小组确定了800例患者的初始大块疾病和600例患者的残余疾病。专家组建议根据1084名患者中的934名患者的随机分组继续治疗,并独立于1084名患者中的145名患者的随机分组继续进行加法治疗。结论:研究表明,有效的化疗后,RT可以大大降低。但是,由于在非RT臂中有10%的患者受到照射,因此无法证明非RT策略的等效效果。根据专家小组的建议,合并RT的实质限制似乎是可能的,而不会降低有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号